206 related articles for article (PubMed ID: 37600055)
1. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure.
Vergaro G; Gentile F; Aimo A; Januzzi JL; Richards AM; Lam CSP; de Boer RA; Meems LMG; Latini R; Staszewsky L; Anand IS; Cohn JN; Ueland T; Gullestad L; Aukrust P; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Gamble GD; Ling LH; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Devlin G; Lund M; Giannoni A; Passino C; Emdin M
ESC Heart Fail; 2022 Aug; 9(4):2084-2095. PubMed ID: 35510529
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
Aimo A; Januzzi JL; Vergaro G; Richards AM; Lam CSP; Latini R; Anand IS; Cohn JN; Ueland T; Gullestad L; Aukrust P; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Gamble GD; Ling LH; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Passino C; Emdin M
Eur J Heart Fail; 2020 Nov; 22(11):2078-2088. PubMed ID: 31919929
[TBL] [Abstract][Full Text] [Related]
4. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
[TBL] [Abstract][Full Text] [Related]
5. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
8. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment.
Oghina S; Josse C; Bézard M; Kharoubi M; Delbarre MA; Eyharts D; Zaroui A; Guendouz S; Galat A; Hittinger L; Fanen P; Teiger E; Mouri N; Montestruc F; Damy T
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768388
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
11. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Left Ventricular
Clerc OF; Datar Y; Cuddy SA; Bianchi G; Taylor A; Benz DC; Robertson M; Kijewski MF; Jerosch-Herold M; Kwong RY; Ruberg FL; Liao R; Di Carli MF; Falk RH; Dorbala S
medRxiv; 2023 Sep; ():. PubMed ID: 37745589
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
Januzzi JL; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Verma S; Vedin O; Iwata T; Brueckmann M; Packer M; Anker SD;
JACC Heart Fail; 2022 Jul; 10(7):512-524. PubMed ID: 35670067
[TBL] [Abstract][Full Text] [Related]
14. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
Vergaro G; Castiglione V; Aimo A; Prontera C; Masotti S; Musetti V; Nicol M; Cohen Solal A; Logeart D; Georgiopoulos G; Chubuchny V; Giannoni A; Clerico A; Buda G; Patel KN; Razvi Y; Patel R; Wechalekar A; Lachmann H; Hawkins PN; Passino C; Gillmore J; Emdin M; Fontana M
Eur J Heart Fail; 2023 Mar; 25(3):335-346. PubMed ID: 36597836
[TBL] [Abstract][Full Text] [Related]
15. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
16. Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease.
Vergaro G; Aimo A; Januzzi JL; Richards AM; Lam CSP; Latini R; Staszewsky L; Anand IS; Ueland T; Rocca HB; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Gustafsson I; Eggers KM; Huber K; Gamble GD; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Emdin M; Passino C
J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):28-36. PubMed ID: 34839321
[TBL] [Abstract][Full Text] [Related]
17. Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure.
Vergaro G; Aimo A; Campora A; Castiglione V; Prontera C; Masotti S; Musetti V; Chianca M; Valleggi A; Spini V; Emdin M; Passino C
Amyloid; 2021 Dec; 28(4):252-258. PubMed ID: 34396857
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
19. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
[TBL] [Abstract][Full Text] [Related]
20. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
